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a b s t r a c t
Abdominal pain is an important symptom in most patients with pancreatic ductal adenocarcinoma
(PDAC). Adequate control of pain is often unsatisfactory due to limited treatment options and signiﬁcant
variation in local practice, emphasizing the need for a multidisciplinary approach. This review contends
that improvement in the management of PDAC pain will result from a synthesis of best practice and
evidence around the world in a multidisciplinary way. To improve clinical utility and evaluation, the
evidence was rated according to the GRADE guidelines by a group of international experts. An algorithm
is presented, which brings together all currently available treatment options. Pain is best treated early on
with analgesics with most patients requiring opioids, but neurolytic procedures are often required later
in the disease course. Celiac plexus neurolysis offers medium term relief in a substantial number of
patients, but other procedures such as splanchnicectomy are also available. Palliative chemotherapy also
provides pain relief as a collateral beneﬁt. It is stressed that the assessment of pain must take into ac-
count the broader context of other physical and psychological symptoms. Adjunctive treatments for pain,
depression and anxiety as well as radiotherapy, endoscopic therapy and neuromodulation may be
required in selected patients. There are few comparative studies to help deﬁne which combination and
order of these treatment options should be applied. New pain therapies are emerging and could for
example target neural transmitters. However, until better methods are available, management of pain
should be individualized in a multidisciplinary setting to ensure optimal care.
© 2018 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction and methods
Pancreatic ductal adenocarcinoma (PDAC) presents in different
ways and often at an advanced stage. Abdominal pain is an
important presenting symptom in about 60% of patients [1] and
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becomes a feature in almost all patients at some stage during the
course of the disease. It is a common disabling symptom with
several causes, and often difﬁcult to treat, requiring multidisci-
plinary management for effective control. Pain is also a major
predictor of outcome and survival. A striking ubiquitous patho-
logical feature of PDAC is perineural invasion, which might explain
its propensity to cause pain.
Recently published guidelines reveal a lack of standardized
assessment and management of pain associated with PDAC. Most
recommendations for its management are offered within selected
specialties, reﬂecting signiﬁcant variation in practice and thus
emphasizing the need for a multidisciplinary approach. The varia-
tion in recommendations may simply reﬂect customary practice,
but also the paucity of evidence on which to base the
recommendations.
This review contends that improvement in the management of
PDAC pain will result from a synthesis of best practices and evi-
dences from around the world, to integrate the many treatment
options, including pharmaceuticals, endoscopic and endosono-
graphic interventions, surgery, neurolysis, neuromodulation,
radiotherapy, psychotherapy, nursing and supportive care.
Accordingly, the authors were selected to include a wide range of
specialists with clinical and research experience in cancer pain
management within relevant specialties. The authors were
assigned to make recommendations on PDAC pain related issues
and giving best available evidence. To improve clinical utility, most
recommendations were framed for routine clinical practice. To
score the strength of the evidence a modiﬁed GRADE method was
used (http://www.uptodate.com/home/grading-tutorial). Finally,
the level of agreement for the stated recommendation was deter-
mined by the authors independently voting on-line. Further details
relating to methodology and a fuller discussion are available
(supplementary material on-line).
Pathogenesis of pain in PDAC
The pathogenesis of pain in PDAC is multifactorial and encom-
passes neuropathic, visceral and somatic mechanisms. Quality
assessment: moderate; Recommendation: moderate; Agreement:
strong
The majority of patients with PDAC experience a chronic pain
syndrome that is multifactorial in origin [2]. It entails neuropathic
mechanisms due to neural inﬁltration by cancer cells. However, the
pathogenesis of pain in PDAC is additionally complex in most cases
with evidence of cross talks between pancreatic nerves, vascular
system, pancreatic stellate cells and cancer cells. This is reﬂected in
management that should target several mechanisms. In addition,
pain can be due to invasion of other visceral and somatic structures.
For details and references, see supplementary material.
Pain assessment in PDAC
Pain should be assessed in the context of many other physical and
psychological symptoms, with an emphasis on severity, quality,
distress and functional consequences. Although there has been focus
on pain intensity, pain interference with quality of life should also be
addressed. Quality assessment: moderate; Recommendation: strong;
Agreement: strong
Pain should be assessed in the context of other multiple physical
and psychological symptoms, with an emphasis on severity, quality,
distress and functional consequences from a patient's perspective
[3]. As pain in PDAC shares mechanisms with those in chronic
pancreatitis, assessment tools used in this disease may be adopted
to patients with pancreas cancer [4]. Numerical scales, such as the
visual analogue scale, are commonly applied to assess the intensity
of pain, but should be combined with a standardized registration of
the temporal pain pattern [5]. Patients with PDAC have a very high
prevalence of depressed mood, which is higher than other cancers
with similar prognoses [6] and in many cases disturbed sleep and
fatigue should also be recorded [7]. Pain assessment should also be
supplemented with measurement of quality of life (QoL) using in-
struments such as the Short-FormHealth Survey 36 (SF-36) and the
European Organization for Research and Treatment of Cancer
(EORTC) QLQ-C30 [8,9].
Secondary reasons for pain
Pain due to complications associated with treatment and side ef-
fects of medication is frequent and should always be considered as
additional reason for pain, especially because treatment is often
effective. Quality assessment: low; Recommendation: moderate;
Agreement: strong
Adverse effects and complications due to surgery, endoscopic,
pharmacological and oncological treatments are important cau-
ses of morbidity in many patients and should be considered as
additional sources of pain (Table 1). As management is often
effective, these causes of pain should not be overlooked. Pain can
be due to chemotherapy and irradiation, and related to neurop-
athy and enteritis [10]. Anastomotic and peptic ulcers are com-
mon and there should be a low threshold for endoscopic
diagnosis. Although strong opioids are often used to relieve pain,
they have the potential to produce substantial side effects,
including constipation, abdominal pain and opioid induced
hyperalgesia that can mimic pain due to PDAC (see section on
analgesics). Complications of surgical and endoscopic treatments
can also be the cause of pain. These include anastomotic leaks,
intra-abdominal collections, acute pancreatitis, perforation and
adhesions [11]. Obstruction of the bile duct is almost universal in
PDAC of the head of pancreas, while obstruction of the duo-
denum occurs in up to a quarter of these patients. In patients
with unresectable, metastatic and recurrent PDAC, biliary and
gastric outlet obstructions are best managed with self-expanding
metal stents without the need for surgical bypass, because they
have been demonstrated to be safe and effective [12]. Abdominal
discomfort can be due to maldigestion following pancreatic
resection from a possible combination of exocrine pancreatic
insufﬁciency, bile acid malabsorption and bacterial overgrowth
[4,12]. Advanced PDAC may cause pain due to direct invasion into
adjacent organs but also from metastases, most commonly to
bone, liver and lung [13].
Pain management algorithm
Pain management in PDAC should be individualized, multidisci-
plinary and follow an algorithm. Quality assessment: moderate;
Recommendation: strong; Agreement: strong
Pain management in PDAC should be individualized, but it
will also depend on local expertise and skills. In many clinical
settings, the treatment of pain follows traditional approaches and
several treatment modalities are often overlooked. There is an
overall consensus by pain specialists that optimal management
of cancer pain should be multidisciplinary [13]. This is illustrated
in Fig. 1, where most treatment options are included. The
different treatments are often started in parallel, although the
sequence of treatments will often depend on stage of PDAC and
availability of treatment modalities and expertise. Hence, the
algorithm in Fig. 1 shall not be regarded as deﬁnitive but as
guidance. With a multidisciplinary approach, it is imperative that
patients have rapid access to a lead health care professional to
coordinate disciplines and taking overall responsibility. Ideally,
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this would be an expert pancreatologist/surgeon/oncologist who
should work with a pain or palliative care specialist. Because the
progress of PDAC and pain is unpredictable, it is important that
patients are well monitored and treatment adjusted.
Non-invasive management of PDAC
Pancreatic enzyme replacement therapy
Pancreatic enzyme replacement therapy may diminish pancreas
secretion and normalize gut function, and as such alleviate abdominal
Table 1
Secondary reasons for pain in patients with PDAC.
Suggested investigation Treatment
Anastomotic and peptic ulcers Gastroscopy Proton pump inhibitors
H. Pylori eradication
Side-effects to opioids Clinical judgement Tapering of medication
Co-administration of laxatives in patients on opioid therapy
Side effects to chemotherapy and irradiation Clinical evaluation Local treatment and drugs against neuropathy
Somatic pain with irradiation to the abdomen Objective assessment of the back etc. Targeted against the somatic pain
Surgical end endoscopic complications: Anastomosis
leaks or strictures, intraabdominal adhesions, pancreatitis
Imaging Conservative treatment, endotherapy or surgery
Duodenal and biliary obstruction Magnetic resonance imaging Stent placement
Exocrine pancreatic insufﬁciency Pancreatic function testing Enzyme replacement therapy
Bacterial overgrowth Breath testing Antibiotics
Bile acid malabsorption Se-HCAT scan Cholestyramine
Delayed gastric emptying Gastroscopy, scintigraphy Pro-kinetics
Metastasis and tumor growth to neighbour organs Imaging Dependent on localization
Se-HCAT: selenium homocholic acid taurine.
Fig. 1. Simpliﬁed algorithm showing the treatment possibilities for optimal management of pain in patients with pancreatic ductal adenocarcinoma. In most cases, the algorithm
cannot be strictly followed and combination therapies are necessary. The recommendation is to consider whether pain intensity and effect on quality of life is sufﬁciently severe to
justify treatment, given the potential side effects. In case there is indication for pain management the following is suggested: 1) First it shall be considered whether there can be
secondary reasons for pain as this often needs speciﬁc treatments. 2) The next step is to evaluate whether local factors such as strictures on the main pancreatic duct need
endoscopical or surgical treatment. 3) Primary pain due to tumor inﬁltration of the nerves and local pressure is treated with a) chemotherapy according to performance status and
pancreatic enzymes as well as b) analgesics, see speciﬁc section for detail. In case this is insufﬁcient or there are too many side effects, c) neurolysis is considered. The neurolytic
treatment depends on local expertise, and timing is important, see speciﬁc section. In many patients d) adjuvant therapy with antidepressants and anxiolytics that also have
analgesic properties are used, and complimentary therapy such as with acupuncture may be used. In some cases, especially when other procedures have failed, treatment with e)
radiotherapy or HIFU can also be used. Finally, 4) supportive care and 5) psychosocial interventions are mandatory in the multidisciplinary approach to pain management. * In
terminal disease spinal application of opioids, anesthetics and adjuvant analgesics may be used for palliation. GI: gastrointestinal, PCM: paracetamol, NSAID: non-steroidal anti-
inﬂammatory drugs, SNRI: serotoninenorepinephrine reuptake inhibitors, TCA: tricyclic antidepressants, BZD: benzodiazepines, TENS: transcutaneous electrical nerve stimulation,
HIFU: high intensity focused ultrasound.
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pain. Quality assessment: moderate; Recommendation: weak; Agree-
ment: weak
Pancreatic enzyme replacement therapy is used for the man-
agement of exocrine pancreatic insufﬁciency in patients with PDAC.
but it may also exert an analgesic effect. The proposed pain reliving
mechanism of action is the ability of pancreatic enzymes to degrade
cholecystokinin (CCK) releasing factor in the duodenum, whereby
CCK-levels are suppressed [14]. In addition to the effects mediated
through CCK pathways, normalization of digestion following
enzyme replacement therapy may also improve abdominal symp-
toms. However, their effect on pain in PDAC is not proven.
Chemotherapy
Chemotherapy can reduce pain likely by decreasing tumor load.
Quality assessment: moderate; Recommendation: strong; Agreement:
conditional
Chemotherapy in unresectable patients may decrease pain by
reducing tumor growth, local neural invasion and inﬂammation. In
a meta-analysis in patients with metastatic PDAC, pain relief
following chemotherapy was consistently seen for most included
studies evaluating pain [15]. Previous studies have shown that
gemcitabine compared with 5FU resulted in increased survival and
reduced pain [16]. Gemcitabine-based combinations showed no
consistent beneﬁt for pain compared with single-agent gemcita-
bine [17]. The newer regimens FOLFIRINOX (oxaliplatin, irinotecan,
ﬂuorouracil and leucovorin) and gemcitabine/nab-paclitaxel have
shown improved survival compared to gemcitabine, and are at
present considered standard treatment for patients with good
performance status [17,18], although time until deterioration of
pain is longer for FOLFIRINOX than with gemticabin [15].
Analgesics
Currently the guidelines for analgesic therapy in PDAC follows the
principles of the “analgesic ladder” provided by the World Health
Organization. However, experimental treatment and other analgesics
may be beneﬁcial in the individual patient. In end stage disease, more
aggressive treatment modalities are often needed. Quality assessment:
moderate; Recommendation: strong; Agreement: strong
The “analgesic ladder” is a stepwise escalation of drugs with
increasing analgesic potency until pain relief is obtained [19] (Fig. 1,
for details see supplementary material). Analgesics should prefer-
ably be administered by the oral route (Table 2) at regular intervals.
Breakthrough pain is treated with e.g., fast-acting on-demand
opioids such as fentanyl. To facilitate the clinical use, the authors'
personal recommendations are also shown (Table 2). The most
important drug classes are brieﬂy described below:
Non-opioid analgesics are used as the ﬁrst step in pain man-
agement. Paracetamol may be sufﬁcient for patients in whom the
pain intensity is mild to moderate. Non-steroidal anti-inﬂamma-
tory drugs (NSAIDs) are normally avoided, but may be used with a
Table 2
Recommended oral analgesics for treatment of PDAC.
Drug class Examples* Comments
Non-opioid analgesics paracetamol 1 g x 4 Used for milder pain. Due to gastrointestinal and cardiac side effects NSAIDS should
normally be avoided. Metamizole may also be considered.
Weak opioids tramadol CR 50e200mg x 2 Codeine and tramadol potentiate the effect of non-opioid analgesics. Both are
prodrugs, metabolized to active opioids and may result in the same side effects.
Strong opioids oxycodone PR starting at 15mg x 2 Addiction is not of major concern in PDAC associated with short life-expectancy, but
escalation of dose can be problematic and some patients may develop opioid-
induced hyperalgesia. Due to potential organ failure during progression of disease
drugs without active metabolites are preferred.
Anticonvulsants pregabalin titrated from 75mg to 300mg x 2 daily The therapeutic gain is often limited due to the side effects (mainly drowsiness and
dizziness), but often these vanish during treatment
TCA amitriptyline 10e50mg at nighttime Side effects limit their use. The effects appear after several weeks of treatment. If one
TCA does not work, another may be effective.
SSRI citalopram titrated up to 40mg at nighttime This class is not an effective analgesic, but may be preferred by some patients in case
of comorbid anxiety and depression
SNRI duloxetine titrated up to 120mg at nighttime The effects of SNRI's are less well documented in cancer pain. They may be used
when neuropathic pain is suspected, and for comorbid anxiety or depression
Anxiolytics diazepam 5mg x 3 Have limited, if any, analgesic effect, but may dampen anxiety
Anti-psychotics levomepromazane titrated up to 100mg daily May potentiate the analgesic effect in selected patients as an augmentation strategy
a-adrenergic agents clonidine titrated to 50 mg x 2 daily May potentiate analgesia when used as add on to the existing treatment, however
side effects limit its use. Most evidence support parenteral and intrathecal use
NMDA inhibitors ketamine titrated up to 50mg x 3 daily As the strongest NMDA inhibitor ketamine may be effective, but side effects are
often severe (treated with concomitant administration of benzodiazepines).
Absorption following oral use is variable but can be used and is suggested here
Cannabinoids nabilone dose 1e2mg, up to 6mg daily Mostly used as adjunctive pain medication and useful for nausea, appetite and sleep.
Small pain reduction and central nervous system side effects limit use in some
patients, considered as third line agent
Steroids dexamethasone 8mg daily The anti-inﬂammatory effects may be beneﬁcial in selected cases
Anti-cholinergic drugs hyoscine titrated to 20mg x 4 Can be adjuvant therapy for bowel obstruction
GABA-agonists baclofen titrated from 5 to 25mg x 3 May be effective in neuropathic pain but is seldom used
Setrons ondansetrone 8mg x 2 Normally used against nausea but may have an analgesic effect
Somatostatin analogues octreotide depot 20mg every 4th week May be effective in bowel obstruction and potentially also has an analgesic effect.
Oral use not possible, but injections with depot formulations may be used
NSAID: non-steroidal anti-inﬂammatory drugs.
TCA: tricyclic antidepressants.
SSRI: selective serotonin reuptake inhibitors.
SNRI: serotonin-noradrenalin reuptake inhibitors.
BZD: benzodiazepines.
GABA: gamma-aminobutyric acid.
* Examples are the authors own suggestions and reﬂect their normal practice. This varies between countries and regions and is dependent on traditions, availability of the
drugs etc., and can only be regarded a suggestion for clinical management. For details see text.
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proton pump inhibitor in case of patient preference. Metamizole is
safer for the upper intestinal tract and kidneys than NSAIDs and is
an alternative [20]. For more severe pain, combination therapies
(also with opioids) may be necessary early in the disease. As shown
in Fig. 1, adjuvant analgesics may be added. These are a heteroge-
neous group of drugs, which include antidepressants, anticonvul-
sants, and anxiolytics. In clinical practice, anti-neuropathic
medications, such as gabapentin and amitriptyline, are often used
Most of the analgesics shown in Table 2 have not been systemati-
cally evaluated for pain associated with PDAC. However, pain
mechanisms and symptoms are likely to be similar across different
diseases [21]. In general, combination therapies are often more
effective andmay decrease the risk of side effects if lower doses can
be used for individual drugs [22]. The choice of drugs is also
determined by an assessment of patient co-morbidity, adverse ef-
fects and any desired side effects (such as sleep and anxiolytic
action).
Anxiety and depression can be masked and screening with reli-
able and valid questionnaires can detect signiﬁcant underlying
emotional distress [23]. Such patients may beneﬁt from drugs with
combined analgesic and anti-depressive effects such as
serotoninenorepinephrine reuptake inhibitors (SNRIs) that have
less side effects than traditional tricyclic anti-depressives. Antide-
pressant drugs can also have neuromodulatory analgesic properties
[24]. Psychotherapy should also be considered.
Opioid analgesics are the mainstay in the management of severe
cancer pain. These are highly effective and their appropriate use by
competent clinicians is important. Unfortunately, the drugs are
often difﬁcult to use and treatment may be complicated by severe
adverse effects. The prescriber should therefore follow guideline
recommendations [25e28]. Even with dose escalation, addiction is
seldom a problem in patients with PDAC. Opioids should not be
used alone, but added to a multidisciplinary strategy that includes
all necessary adjuvant analgesics, psychological and social support.
There is enormous variation in opioid availability around theworld,
and insufﬁcient availability can lead to under-treatment [29,30]. In
patients with progressive diseases like PDAC severe renal and he-
patic insufﬁciency may develop over time and some opioids like
codeine, tramadol and morphine require extra caution [25]. All
patients must be fully informed of the proposed therapeutic
strategy and potential side effects. In some cases, the abdominal
pain increases despite an increase in opioid dose, and opioid
induced bowel dysfunction (ileus and constipation) or opioid
induced hyperalgesia (narcotic bowel syndrome) should be sus-
pected [31,32]. Laxatives should be considered for all patients on
opioid analgesia for PDAC pain because of the high risk of con-
stipation. Other strategies include the use of opioid antagonists
with restricted effect on the gut or in the periphery, or in case of
hyperalgesia, opioid rotation or even lowering or tapering off opi-
oids. Patients on opioid therapy must be kept under close clinical
surveillance, and it should be noted that there is considerable in-
dividual variation in both efﬁcacy and side-effects. Not all patients
beneﬁt from opioids and often additional treatments are required.
A trial of an alternative opioidmay also be indicated. Opioid rotation
may be difﬁcult and patients with pain may need higher doses than
patients who are switched because of intolerable side effects
[13,29]. Transdermal administration (patch formulation) may be
useful in patients having trouble with oral intake. Breakthrough
pain can be treated with rapid-onset transmucosal or intranasal
fentanyl formulations. Methadone may be advantageous in many
patients and can be used in small doses as add-on to existing opioid
treatment. Of note, methadone should only by prescribed by phy-
sicians who are familiar with the complex pharmacology and
adverse effect proﬁle of this opioid.
In case of poor pain control, continuous pharmacotherapy by
means of epidural or intrathecal catheters might be considered.
When pain is caused by liver or bone metastases, patients may
beneﬁt from radiotherapy [12].
Supplementary treatments such as cannabinoids, ketamine,
clonidine, benzodiazepines, anti-psychotics and steroids may be
considered in difﬁcult cases [13]. For management of pain in PDAC,
cannabinoid derivatives are mostly prescribed in the palliative
phase. Nausea, low appetite and poor sleep are additional targets.
Although small series report modest pain relief with dronabinol in
gastro-intestinal cancers, sound clinical evidence is lacking
[33e35]. Evidence is scarce for ketamine in cancer pain. The drug
may reduce opioid-induced tolerance and hyperalgesia which is
beneﬁcial for many patients. The mode of administration is still not
standardized with some support for intravenous or subcutaneous
use [36] or intranasal administration [27].
Near the end-of life, pain management for advanced and ter-
minal PDAC can become very challenging and an interdisciplinary
approach, including palliative care specialists is needed. It is
important wherever possible to consider the preferences of the
patient. Depending on the national legal and ethical framework, a
range of supportive care measures can be offered, including
intensive home support, home carewith parenteral opioids, patient
controlled analgesia and palliative sedation. Finally, in some
countries, patients with terminal cancer have the legal right to
request euthanasia or assisted suicide [37].
Invasive management of PDAC
Neurolytic treatment
Neurolysis in PDAC can reduce pain intensity and opioid use, but as
the duration of effect is highly variable it is normally reserved for
palliating patients with advanced stages of disease and short life ex-
pectancy. Celiac plexus neurolysis is most used and bilateral injection
or direct injection in the ganglia is recommended. The endoscopic
approach may decrease the risk of complications. Other procedures
such splanchnicectomy are less well documented and seldom used,
although it may relieve pain for a longer time period. Quality assess-
ment: moderate; Recommendation: strong; Agreement: strong
Neurolytic procedures of the sympathetic nervous system have
been used for nearly a century to treat pain in patients with PDAC
[38]. The rationale is to reduce pain by destruction of the afferent
pathways from pancreas to the brain, and can be done at different
levels (Fig. 2); for more details please see appendix. One of themost
commonly used procedures is celiac plexus neurolysis (CPN).
Importantly, only the upper abdominal visceral pain sensations are
targeted.
Celiac plexus neurolysis
Technique: The classic technique is the bilateral, percutaneous
posterior approach, guided ﬂuoroscopically or with computed to-
mography. When the needle is in the correct position a neurolytic
agent, typically absolute alcohol, is injected around the nerves [39].
In cases of advanced cancers, the analgesic effect of CPN may be
limited [40], and malignant inﬁltration of the plexus is also a pre-
dictor of poor pain response [41]. While a few studies found no
differences between central versus bilateral injections [42,43], a
randomized study and a meta-analysis have shown superiority of
bilateral injections [44,45].
Efﬁcacy: There is evidence that CPN, regardless of the technique
used, improves analgesia and QoL, and decreases opioid con-
sumption [26,46]. Compared with analgesic drugs, there is minimal
superiority, but CPN is associated with fewer adverse effects
[46,47]. Unfortunately, most studies have focused on pain intensity
rather than more composite endpoints [48], and only a few are
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considered of high quality [39,46,49]. Importantly, if malignancy
involves areas of somatic innervation such as the peritoneum or
diaphragm, neurolysis will lose its effect.
Timing: Due to the risk of ﬁbrosis and other complications, CPN
is normally not performed before surgery. Some studies proposed
early intervention [50e53]. However, these observations remain
unproven since CPN was often performed in patients receiving
analgesic drugs [54]. The analgesic effect seems to vanish after 8
weeks [49], and in most patients, pain recurs after 3 months [50].
As only about 30% of patients beneﬁt from repeated CPN [55], this is
normally not offered. As the probability of patients remaining
completely pain free after CPN diminishes with increasing survival
time, the optimal therapeutic window may be in later stages of
disease so the effect is maximal when pain intensity is highest
[53,54]. The arguments against late intervention is that tumor
growthmay involve other organs, where CPN is less effective. There
is signiﬁcant variation in the analgesia duration, and timing will
differ between patients. Overall there is general agreement that
neurolysis is best reserved for patients with advanced disease, and
indicated when strong analgesics are no longer effective or their
side effects increase QoL [56]. Life expectancy, and extent and rate
of disease progression should be considered in individual patients.
Survival: Weak clinical evidence indicates that opioids (as the
alternative to neurolysis) may play a negative role in cancer
development and progression [57,58]. CPN could at least theoreti-
cally be opioid sparing and prolong survival. Additionally, PDAC has
neurotrophic characteristics and as tumor growth may follow the
nerves, destruction of the pathways could be advantageous [59].
Correspondingly, an early study showed prolongation of survival
after performing CPN [50], but this was not reproduced in later
retrospective studies [60] and there is no robust evidence that CPN
affects progression of disease.
Endoscopic ultrasonography-guided celiac plexus neurolysis
(EUS-CPN): This is becoming increasingly popular as it has fewer
risks. Due to the variation of the anatomy of the celiac trunk, EUS
also has the advantage of allowing direct visualization of the celiac
ganglia [61]. The use of Doppler makes it possible to assess the
regional vascular structures and reduce the risk of posterior spread
of the neurolytic agent to the spinal arteries or nerves. Another
advantage is that the procedure can be performed at the same time
as ﬁne needle aspiration for cytology in patients with unresectable
and metastatic PDAC [39,41,62]. Contraindications to EUS-CPN
include uncorrectable coagulopathy, esophageal or cardiac vari-
ces, altered anatomy of the upper digestive tract secondary to
previous surgery, hemodynamic/respiratory instability, large tumor
mass and lymphadenopathy [62].
No large trials have directly compared EUS-CPN with the clas-
sical percutaneous approach, but relief of pain was reported in
54%e88% of cases in several case series together with a decrease in
opioid consumption [41,63e65]. In most case series, the duration of
pain relief in the successful treatment group was reported around a
median of 8e10 weeks and until death in one third of patients
[41,62,66]. Like for the percutaneous approach, bilateral injection of
the celiac plexus seems to provide better pain relief than injecting
at one site [44,65]. Broad neurolysis and direct injection into the
celiac ganglia may also be better than unilateral injections [67,68].
Splanchnic nerve neurolysis
Splanchnicectomy may disrupt more nerve pathways than CPN
(Fig. 2) and is a better alternative when there is a large mass in the
region of the celiac plexus. The procedure is most often performed
thoracoscopically under general anesthesia, but can also be per-
formed ﬂuoroscopically as a day care procedure. Splanchnicectomy
is seldom performed in patients with PDAC despite some evidence
of long lasting pain relief and few complications in observational
series [69e72], possibly because the expertise is not widely avail-
able. Splanchnicectomy with radiofrequency ablation seems less
effective, but reports are limited. A retrospective study showed a
long-lasting effect on pain with no severe complications [73], but
randomized trials are lacking.
Other neurolytic techniques
Combined tumor ablation and celiac plexus neurolysis with EUS
was recently shown to be more effective for pain relief and survival
Fig. 2. Different approaches to neurolytic therapy in PDAC. A: Potential levels of neurolysis. 1) Celiac plexus block; 2) Splancnicectomy; 3) Sympathectomy; 4) Rhizotomy. The two
latter are seldom used. B: Schematic illustration of the most used procedures. 1) Percutaneous transcrural celiac plexus neurolysis; 2) Percutaneous retrocrural splancnic nerve
neurolysis (the thoracoscopic splancnicectomy is not shown); 3) Endoscopic ultrasonography-guided celiac plexus neurolysis (bilateral, broad or intraganglionic neurolysis is the
recommended technique).
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than EUS guided neurolysis alone, and this may be an approach for
future treatment [74]. Other endoscopic techniques include celiac
ganglion irradiation with I-125 impregnated seeds [75,76]. In pilot
studies, this has been shown successful in the short run and a recent
meta-analysis conﬁrmed an effect on pain in 80% of patients [77].
Complications of neurolysis
Although CPN is generally safe, common side effects include
transient orthostatic hypotension, diarrhea and back pain. Neuro-
logical complications related to spasm or thrombosis of the anterior
spinal artery are seldom (<0.15%) seen, but cases of paraplegia have
also been reported [78]. Retroperitoneal hemorrhage and infections
may also develop, and peripancreatic and brain abscesses have
been described [79,80] (see Table 3).
Neuromodulation
Acupuncture is a moderately effective treatment for cancer pain,
including PDAC. The evidence for an analgesic effect from trans-
cutaneous electrical nerve stimulation is weak. The procedures can
be considered as supplementary treatments in selected patients.
Quality assessment: low; Recommendation: weak; Agreement:
conditional
Acupuncture has beenwidely used for cancer pain in China, and
appears to be moderately effective in selected patients [56,81]. An
analgesic effect was found using electro-acupuncture compared
with sham in patients with PDAC, and this effect persisted for up to
two days after cessation of treatment [82]. Acupuncture has few if
any side-effects, but is operator dependent and the effect is nor-
mally short-lasting. Therefore, it can be regarded as a supplemen-
tary treatment to other therapies.
The evidence for an analgesic effect with transcutaneous elec-
trical nerve stimulation (TENS) is weak, but may be helpful in
selected patients [83]. Spinal cord stimulation is rarely used
because it is a more invasive and costly procedure for patients that
have a limited life expectancy. Another approach to neuro-
modulation is vagal stimulation, which might be effective in
selected patients [84].
Radiotherapy and ultrasound
Radiotherapy appears to be effective for PDAC pain, but prospective
evidence is required before it can be generally recommended. Quality
assessment: low; Recommendation: weak; Agreement: conditional
The effect of radiotherapy on pain has been studied both in
patients with chronic pancreatitis [85] and PDAC [86,87], but the
evidence comes from observational studies. It may be suitable for
frail patients and requires further evaluation [88]. A pilot study
showed that stereotactic radiotherapy (CyberKnife) could alleviate
pain in patients withmetastatic PDAC andmay be useful in selected
cases [89].
Pilot data from observational series suggest that high intensity
focused ultrasound (HIFU) improves pain and physical function
[90,91], and this was conﬁrmed in a recent meta-analysis [92].
Despite this, the heterogeneity of the data and the lack of ran-
domized controlled trials prevents making a strong
recommendation.
Endoscopic treatment
Pancreatic ductal stenting can be considered for a small subgroup
of patients with unresectable PDAC in the head of pancreas, dilation of
the main pancreatic duct and severe “obstructive-type” pancreatic
pain. Quality assessment: low; Recommendation: moderate; Agree-
ment: conditional
Several case series have reported that pancreatic ductal stenting
can help to palliate pain [93]. It appears that this is indicated in a
small subgroup of patients with unresectable PDAC in the head of
pancreas, associated with dilation of the main pancreatic duct
(MPD) and with severe pancreatic obstructive-type of pain (see
supplementary material). Pain relief was reported in about 80% of
these cases [93]. A prospective study reported a decrease in pain
intensity and reduced opioid consumption over 16 weeks in 62% of
patients [94]. In another prospective study, it was found that pain
relief was only found in patients with a dilatedMPD [95]. Pancreatic
ductal stenting could therefore be considered in those patients
with unresectable pancreatic cancer in the head of pancreas, severe
“obstructive-type” pancreatic pain, and MPD dilatation. While this
could be considered at the same time as biliary stenting, there is a
lack of randomized controlled studies comparing it with other pain
treatment and it cannot be recommended as a standard of care [96].
Table 3
Frequently asked question about neurolytic therapy.
Clinical question Recommendation
Is CPN better than standard therapy? RCTs have shown that CPN decrease pain and opioid consumption in comparison with conventional therapy, but the
difference in effect is marginal
When shall CPN be done? The timing cannot be predicted by any clinical parameters. Most studies recommend that analgesics are used ﬁrst and
neurolysis done when pain cannot be controlled or opioid consumption is accelerated. As efﬁcacy decrease after 2e3
months it shall be postponed to the later stages of disease and life expectancy taken into consideration
Can CPN be repeated? Technically it can, but is only effective in about 30%, partly because tumor growth may extend to other tissue
Which technique shall be used? The EUS approach is considered safer although evidence is limited, but when available it is recommended. In centers
with major experience in imaging guided percutaneous CPN this may be preferred.
What does tumor localization mean? Localized disease may respond best. Although some studies have shown better effect in certain locations (head, body
tail) there is no consensus
Does CPN prolong survival? Although there may be a theoretical gain, clinical studies do not support an effect on disease progression
Are other techniques for CPN advantageous? There is no solid evidence that other neurolytic techniques are better, but pilot studies seem to indicate that for example
broad neurolysis and combined CPN and tumor ablation gives better response than standard treatment
Has splanchnicectomy any advantages
compared to CPN?
Potentially splanchnicectomy is better when a large mass is present around the celiac plexus and disrupt more nerve
pathways than CPN. However, comparative studies are lacking.
Are there any predictors for effect? Tumor location does not seem to interfere with pain relief, but involvement of the celiac plexus may complicate the
procedure. Involvement of structures outside pancreas may also decrease analgesia as neurolysis only blocks the
sympathetic pathways of visceral pain
Are there any technical considerations? The effect seems to be better when the neurolytic agent has a broad
distribution, and when the celiac ganglia are directly visualized endoscopically and injected
CNP: celiac plexus neurolysis and RCT: randomized controlled trial
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Surgical treatment
The role of surgical treatment to palliate pain associated with PDAC
is extremely limited, although surgery may be rarely indicated for pain
due to duodenal or biliary obstruction. Quality assessment: moderate;
Recommendation: strong; Agreement: strong
Historically, surgical treatments were used for the division of
putative pain pathways, including celiac plexi, splanchnic nerves,
sympathetic chain and spinal nerve roots (see Fig. 2). These surgical
neurolytic procedures have fallen into abeyance with the failure of
evidence for a favorable risk:beneﬁt ratio and with the rise of
minimally invasive alternatives [97]. Pain relief is expected when
complete surgical resection of PDAC is possible, as a surgery ﬁrst
approach or after neoadjuvant therapy. However, pain is most
commonly associated with locally advanced PDAC (either primary
or as recurrence), where there is direct tumor extension beyond the
pancreas, along with perineural and lymphovascular invasion.
Because of the morbidity (including pain), risk of mortality and
delayed recovery, palliative pancreatic resections are no longer rec-
ommended [98]. This is reﬂected in the signiﬁcantly reduced need
for surgery as a palliative intervention, and the increasing use of
palliative chemotherapy for stage IV PDAC [99].
Pain can also be due the invasion of adjacent organs by PDAC,
and surgery may play a role in these circumstances. Stenosis of the
distal bile duct can in some cases give rise to biliary type pain with
obstructive jaundice, but endoscopic biliary stenting is now used in
the vast majority of patients [100]. Stenting of the bile duct rarely
gives rise to painful acute cholecystitis [101], and if antibiotics and
endoscopic treatments are not effective, a percutaneous trans-
hepatic cholecystostomy or cholecystectomy may be required.
Stenting can also be associated with ascending cholangitis and pain
and this necessitates stent exchange. Advanced PDAC can also cause
pain associated with gastric outlet obstruction secondary to
duodenal invasion and stenosis. Historically, surgical treatmentwas
used, but endoscopic duodenal stenting is now preferred [100].
Psychosocial interventions
There is moderate evidence in favor of psychosocial interventions
for cancer pain in general, but the evidence is limited for PDAC. Pooled
data suggest moderate efﬁcacy with pain relief. Quality assessment:
moderate; Recommendation: moderate; Agreement: strong
Anxiety and depressive symptoms are common in PDAC, with
rates higher than for other cancers in most studies [102e106]. In
one study, the severity of depression was linked to increased self-
reported pain [105]. Depression has been linked to signiﬁcantly
poorer QoL [107]; sleep disturbance [108], inadequate cancer
treatment and lower survival rates [109]. Because depression,
anxiety, pain, sleep disturbance and negative or pessimistic
thoughts or attitudes are modiﬁable conditions, proper assessment
and management is essential [110].
There has been no randomized control trial of any behavioral
intervention for patients with PDAC, but an open pilot study
showed a beneﬁcial effect of educational sessions by nurses on QoL
[111]. One opinion article recommended a psycho-oncologist for
PDAC patients to distinguish normal emotional reactions to cancer
which usually resolve within weeks, with appropriate social sup-
port from longer lasting psychiatric conditions requiring psycho-
therapy and psychotropic medications [112].
Suggested psychosocial approaches can be drawn from studies
for other types of cancers with a similar psychological symptom
proﬁle. Supportive therapy, cognitive behavioral therapy, coping
skills training, mindfulness meditation, hypnosis, dignity therapy
and acceptance and commitment therapy have the strongest evi-
dence of efﬁcacy [113e120]. Overall, most studies support the idea
that psychosocial interventions offered early in the cancer course
have a more signiﬁcant beneﬁt than those offered at end-stage
disease [121,122].
Supportive and palliative care
The provision of palliative care to patients with newly diagnosed
and incurable PDAC improves quality of life, reduces depression, and
an analgesic effect is expected. Quality assessment: low; Recommen-
dation: moderate; Agreement: strong
The goal of palliative care, in taking a holistic approach to care
and treatment, is to improve the QoL of patients with advanced
cancer by alleviating symptoms and problems caused by illness and
its treatment [123]. The early provision of palliative and oncology
care in patients with newly diagnosed incurable cancers (including
PDAC) improves QOL, reduces depression symptoms, and enhances
the ability to cope with the diagnosis and prognosis [124,125]. As a
result, an analgesic effect is expected. A recent retrospective study
showed that patients with advanced PDAC beneﬁted from a palli-
ative care programs by requiring less chemotherapy and less
admission to intensive care and hospital [126]. Palliative care of
patients with PDAC should include nutritional support and opti-
mized pancreatic enzyme replacement [12].
Systematic early palliative care was shown to be superior to on-
demand palliative care in terms of QoL (and probably pain relief)
[127]. The actual evidence for the efﬁcacy of early palliative care
interventions is still sparse, but it generally accepted that this
should be recommended for all patients with advanced PDAC.
Conclusion
Unfortunately, most patients with pancreatic ductal adenocar-
cinoma have unresectable disease and succumb to local recurrence
and metastatic disease. Therefore, they often need advanced ther-
apy as part of palliative care. The overall management requires the
coordination of multiple disciplines and this is particularly true for
associated pain, which can be disabling and arises due to a number
of different mechanisms. The assessment of pain must take into
account other symptoms and the broader context of other physical
and psychological symptoms. The many treatment options have
been reviewed and an international, multidisciplinary consensus
obtained, including the strength of recommendation and the extent
of agreement. An algorithm is presented which brings together all
treatment options, but there are few comparative studies to help
deﬁne which combination and order of these treatment options
should be applied to the management of individual patients. This
might go some way to explaining the variation of practice and
opinion, amongst international experts. Management of pain
should always be multimodal and individualized, and will depend
on factors such as disease stage, patient preferences and local
expertise. However, it is strongly recommended that all possible
treatment options are considered, preferably in a multidisciplinary
setting, to ensure optimal care.
Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.pan.2018.04.008.
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